tbuckley/cabot-search huggingface dataset:
PP-012 Cytokine gene polymorphisms, cytokine levels and risk of colorectal neoplasia in the screened population of northeast Scotland
Authors: U Basavaraju, F Shebl, A J Palmer, G L Hold, C S Rabkin, E M El-Omar
Journal: Gut (2010)

<h3>Introduction</h3> Chronic inflammation plays a key role in the pathogenesis of many cancers but its role in colorectal neoplasia (CRN) is not clear. Our aim was to investigate the effect of cytokine gene polymorphisms and circulating cytokine levels on risk of CRN in North East Scotland, which has a high incidence of colon cancer. <h3>Methods</h3> Subjects underwent a complete bowel cancer screening colonoscopy and were free of IBD. Blood-derived DNA was used to genotype polymorphisms in the IL1B, IL1-RN, IL6, IL8, IL10, PTGS2 and TNFA genes using 5′ nuclease taqman assays. Serum high-sensitivity C-reactive protein (Hs-CRP) and plasma levels of six cytokines (IL-1β, IL-4, IL-6, IL-8, IL-10 and TNF-α) were measured. Subjects with adenomas with or without cancer (cases) were compared against subjects with no evidence of adenoma or cancer (controls). For Hs-CRP and plasma cytokines, levels were divided into tertiles and compared against each other. χ<sup>2</sup> test was used for comparing cases and controls. Logistic regression analysis adjusting for gender was used and odds ratios (OR) with 95% CI were calculated. <h3>Results</h3> For the genetic study, a total of 295 cases were compared with 398 controls. Mean age of the cases was 64.4 years compared to 62.3 years in controls (p&lt;0.01) and males were overrepresented in the cases (66.1% vs 53.3% in controls, p&lt;0.001). Regular use of NSAID was more common among controls compared to cases (p&lt;0.0001). The pro-inflammatory IL-1B-31 C*C genotype increased the risk of having an adenoma by 1.9-fold compared to the IL-1B-31 T*T genotype (95% CI 1.2 to 3.0). Among subjects with adenoma, the pro-inflammatory IL8-251-A*A genotype increased the risk of having a high-risk lesion (cancer, large adenoma, or multiple adenomas) compared to the IL-8-251 T*T + T*A genotypes (OR 3.4, 95% CI 1.7 to 7.0). None of the other polymorphisms showed any significant associations. Having a Hs-CRP level in the highest tertile compared to the lowest two tertiles increased the risk of having an adenoma by 1.6-fold (95% CI 1.0 to 2.6) and cancer by 2.1-fold (95% CI 0.9 to 5.0). Among subjects with adenomas, having an IL-8 plasma level in the highest tertile compared to the lowest two tertiles doubled the risk of having a high-risk lesion. <h3>Conclusion</h3> Proinflammatory cytokine gene polymorphisms in IL-1B increase the risk of developing adenomas while those in the IL-8 increase the risk of progression to advanced lesions. Hs-CRP and IL-8 levels predict presence and severity of CRN. Along with the NSAID findings, our data point to inflammation as an underlying pathogenetic mechanism in this cancer.
A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08
Authors: N. Wolmark, G. Yothers, M. J. O'Connell, S. Sharif, J. N. Atkins, T. E. Seay, L. Feherenbacher, S. O'Reilly, C. J. Allegra
Journal: Journal of Clinical Oncology (2009)

LBA4 Background: The primary aim of this two-arm randomized prospective study was to determine whether mFOLFOX6 plus bevacizumab (mFF6+B) would prolong disease-free survival (DFS) compared to mFOLFOX6 (mFF6) alone. Methods: Between September 2004 and October 2006, 2,672 patients with follow-up (1,338 and 1,334 in respective arms) with stage II (24.9%) or III carcinoma of the colon were randomized to receive either mFF6 (oxaliplatin 85 mg/m 2 IV d1, leucovorin 400 mg/m 2 IV d1, 5-FU 400 mg/m 2 IV bolus d1, and 5-FU 2400 mg/ m 2 CI over 46 hrs (d1+2) q14d × 12 cycles) or mFF6+B (same mFF6 regimen + bevacizumab 5 mg/kg IV q 2 wks × 1 yr). The primary end point was DFS. Events were defined as first recurrence, second primary cancer, or death. Results: The median follow-up for patients still alive was 36 months. The hazard ratio (HR: FF6+B vs. mFF6) was 0.89; 95% CI (0.76=1.04); p=0.15. Data censored at intervals disclosed an initial benefit for bevacizumab that diminished over time: The smoothed estimate of the DFS HR over time indicated that bevacizumab significantly reduced the risk of a DFS event during the interval from 0.5 to 1.0 year. There was no evidence that patients receiving bevacizumab had a worse DFS compared to those receiving mFF6 alone following treatment. Conclusions: The addition of bevacizumab to mFF6 did not result in an overall statistically significant prolongation in DFS. There was a transient benefit in DFS during the one-year interval that bevacizumab was utilized. Consideration may be given to clinical trials assessing longer duration of bevacizumab administration. Supported by PHS grants U10CA-12027, -69974, -37377, and -69651 from the NCI and a grant from Genentech, Inc. [Table: see text] No significant financial relationships to disclose.
iPSC-derived β cells model diabetes due to glucokinase deficiency
Authors: Haiqing Hua, Linshan Shang, Hector Martinez, Matthew Freeby, Mary Pat Gallagher, Thomas Ludwig, Liyong Deng, Ellen Greenberg, Charles LeDuc, Wendy K. Chung, Robin Goland, Rudolph L. Leibel, Dieter Egli
Journal: Journal of Clinical Investigation (2017)
Sudden infant death syndrome: resurgent research offers hope
Authors: J. W. Zylke
Journal: JAMA (1989)

A SYNDROME of apparently healthy infants dying suddenly and inexplicably was described almost a century ago and has been the subject of systematic study for more than 40 years. But understanding of crucial aspects of sudden infant death syndrome (SIDS)—what causes it, which infants are at risk, and how to prevent it—is still limited. Leaders in the field are hoping to change this by providing direction and opportunities for intensified research. The opportunities are in the form of additional funding. According to L. Stanley James, MD, chair of neonatology at Columbia Presbyterian Medical Center in New York City, "the government is now having a special rejuvenation of SIDS research, and over the next 5 years, they are going to be putting in $30 to $40 million." The direction is supplied through a 5-year research plan recently proposed by a panel of experts under the direction of the National Institute of
Paediatrics
Authors: P. Catzel
Journal: BMJ (1955)

<h3>ABSTRACT</h3> This work explored hybrid films of silver nanowires (AgNWs) with indium-zinc oxide (IZO) for developing high-performance and low-cost electrocorticography (ECoG) electrodes. The transparent hybrid films achieved a sheet resistance of 6 Ω/sq enabling electrodes with 500 μm diameter to reach an impedance of 20 kΩ at 1 kHz and a charge storage capacity of 3.2 mC/cm<sup>2</sup>, an improvement in properties over IZO electrodes, whose performance is on par with the classical tin doped indium oxide (ITO). Characterization of light-induced artifacts was performed showing that light intensities &lt;14 mW/mm<sup>2</sup> elicit minimal electrical potential variation, which falls within the magnitude of baseline noise. The validation of electrodes in vivo was achieved by recording electrical neural activity from the surface of rat cortex under anaesthesia. Moreover, the presence of the hybrid films did not cause distortion of light during fluorescence microscopy. This study highlighted the capabilities of the hybrid structure of AgNWs with IZO, that can be fabricated with industrially-established processes at low cost, to be used for transparent ECoG electrodes, offering a new way to record neural electrical activity on a large and fast scale with direct visualization of neurons.
Resident-matching programs: the students' viewpoint
Authors: C. H. Slater
Journal: JAMA (1969)

In recent years, medical students and educators have been interested in obtaining, within a specialty, a uniform appointment date for first-year residents. The purpose is to allow the student of medicine time enough to select wisely his field of graduate medical education and seek intelligently what would be for him the "best" graduate program. In seeking mechanisms for implementing this uniform appointment date, most of the specialty groups have discussed the advantages and disadvantages of resident matching; only two have actually tested the idea. Resident matching as discussed in this paper refers only to the appointment of<i>first-year</i>residents. The Student American Medical Association, after having examined the various mechanisms which might be employed to implement uniform appointment dates, voted at their 1968 House of Delegates meeting to seek the implementation of additional resident-matching programs. The decision was prompted by the dual realization that the applicants are the primary beneficiaries
Structured advance planning. Is it finally time for physician action and reimbursement?
Authors: L. Emanuel
Journal: JAMA (1995)

IF THERE is one striking thing about the advance directives movement, it is the contrast between the overwhelming endorsement of advance directives from all corners of society and their virtual nonuse. Why do they meet with simultaneous deference and diffidence? One possible explanation is that the whole paradigm is wrong—perhaps the autonomy model that motivates the advance directives movement is mistaken. Another possible explanation is that the basis for the movement is right but too much was expected too fast. Perhaps "doing advance directives" is not so simple, and like other medical interventions, advance planning has to develop and find its appropriate place before it is trustworthy. <h3>An Argument for Slow Ripening</h3> There is not much ground for the more radical explanation that the model of autonomy on which advance directives are founded is flawed. Recently, commentators have pointed out that people are not atomistic. Certainly, if people are like
Life Expectancy
Authors: M.E. Wilson
Journal: JAMA (1974)

<h3>To the Editor.—</h3> Life assurance companies need a reliable yet simple way to estimate life expectancy. Many palmists believe that the length of the life line can be used to predict life expectancy.<sup>1</sup> We tested this idea in 51 cadavers of known age at death, using a map measurer to determine the length of the life line in each hand. The heel-crown length measurement enabled correction for differences in body size. Correlations between age and other variables (Table) were obtained through a matrix program (BMD 02D) using a CDC 6400 digital computer. The critical value of correlation coefficient for significance (<i>P</i>=.05) is .27 (N = 51). Within the Table, no value exceeded the critical value, and therefore no correlation was significant. The life line was interrupted in one hand in six subjects; in these, the total length of that line was used in the calculations. Fortunately, the level of
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Journal: New England Journal of Medicine (1989)

The Physicians' Health Study is a randomized, double-blind, placebo-controlled trial designed to determine whether low-dose aspirin (325 mg every other day) decreases cardiovascular mortality and whether beta carotene reduces the incidence of cancer. The aspirin component was terminated earlier than scheduled, and the preliminary findings were published. We now present detailed analyses of the cardiovascular component for 22,071 participants, at an average follow-up time of 60.2 months. There was a 44 percent reduction in the risk of myocardial infarction (relative risk, 0.56; 95 percent confidence interval, 0.45 to 0.70; P<0.00001) in the aspirin group (254.8 per 100,000 per year as compared with 439.7 in the placebo group). A slightly increased risk of stroke among those taking aspirin was not statistically significant; this trend was observed primarily in the subgroup with hemorrhagic stroke (relative risk, 2.14; 95 percent confidence interval, 0.96 to 4.77; P = 0.06). No reduction in mortality from all cardiovascular causes was associated with aspirin (relative risk, 0.96; 95 percent confidence interval, 0.60 to 1.54). Further analyses showed that the reduction in the risk of myocardial infarction was apparent only among those who were 50 years of age and older. The benefit was present at all levels of cholesterol, but appeared greatest at low levels. The relative risk of ulcer in the aspirin group was 1.22 (169 in the aspirin group as compared with 138 in the placebo group; 95 percent confidence interval, 0.98 to 1.53; P = 0.08), and the relative risk of requiring a blood transfusion was 1.71. This trial of aspirin for the primary prevention of cardiovascular disease demonstrates a conclusive reduction in the risk of myocardial infarction, but the evidence concerning stroke and total cardiovascular deaths remains inconclusive because of the inadequate numbers of physicians with these end points. (N Engl J Med 1989; 321: 129–35.)
A NEW MEDICO-LEGAL QUESTION.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Watts Right
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Twentieth Annual San Francisco Cancer Symposium
Journal: JNCI Journal of the National Cancer Institute (1984)

Journal Article Twentieth Annual San Francisco Cancer Symposium Get access JNCI: Journal of the National Cancer Institute, Volume 73, Issue 6, December 1984, Page 1491, https://doi.org/10.1093/jnci/73.6.1491-b Published: 01 December 1984
Medical Education, Registration and Hospital Service
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quantitation of serum HCV RNA with branched DNA signal amplification assay and response to IFN therapy P. Marcellin, M. Martinot-Peignoux, M. Pouteau, S. Erlinger and JP. Benhamou. Service d'Hépatologie and INSERM U24, Hôpital Beaujon, Clichy, France
Journal: Hepatology (1994)
Textbook of Physical Therapy
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Journal summary
Journal: Annals of the Rheumatic Diseases (1991)

LEADERThe impact of our expanding aging population and rheumatology p 3 Our population in the United Kingdom is changing in its demographical mix.We are beginning to see the effects of the various baby booms and the undoubted fact that people are living longer.The incidence of arthritis rises with age and its pattern changes.The size of families is changing.All this is likely to have a great effect on the specialty of rheumatology.
Lectures on Conditioned Reflexes. Volume II: Conditioned Reflexes and Psychiatry
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Report on a Study of the Nasopharyngeal Bacterial Flora of a Group of the Manchester Population During the Period July, 1925, to September, 1927.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Therapy for chronic hepatitis B with lymphoblastoid interferon-α and levamisole
Authors: G Fattovich
Journal: Hepatology (1992)

About one third of patients with chronic hepatitis B show a sustained response when treated with interferon-α. Combining interferon-α with immunomodulators might be a way to increase response rate. The aim of this study was to compare the efficacy of lymphoblastoid interferon-α given alone with its efficacy when combined with levamisole in chronic hepatitis B. Forty-five patients with HBeAg-positive chronic hepatitis were randomly selected (with stratification for ALT levels) to receive a 6-mo course of combination therapy with lymphoblastoid interferon-α (5 million units/m2 three times per week) and levamisole (150 mg three times per week) or lymphoblastoid interferon at the same dose regimen and a matching placebo. Final evaluation 18 mo after randomization revealed a loss of both HBeAg and hepatitis B virus DNA with ALT normalization in 38% of patients treated with interferon-α alone and in 10% of patients receiving combination therapy. The higher response rate observed in patients treated with interferon-α alone was maintained after stratification for basal ALT levels (i.e., higher [45% vs. 10%] or lower [31% vs. 9%] than three times the upper normal value). The length of time to sustained HBeAg clearance was significantly (p < 0.05) shorter in patients receiving monotherapy than in patients receiving combination therapy. Blinded histological assessment revealed improvement in 44% of patients treated with interferon-α alone compared with improvement in 6% of patients receiving combination therapy. These results indicate that levamisole has no additive effects when combined with interferon-α in the treatment of HBeAg-positive chronic hepatitis. (HEPATOLOGY 1992;16:1115–1119.)